No Data
Express News | Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
Press Release: Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Mineralys Therapeutics (MLYS) Files Lorundrostat NDA Following Positive Clinical Milestones
Mineralys Targets Sleep Apnea and Hypertension With Lorundrostat: What Investors Should Watch
We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate
GLP-1 Spillover, AI Empowerment... Could Biopharmaceuticals Become the 'Alternative' to Tech Stocks in 2026?
Citi noted that the indications for GLP-1 are expanding from weight management to cardiovascular and nervous system applications, alongside an anticipated expansion of Medicare coverage and the launch of Eli Lilly and Co’s oral medication orforglipron; AI is fully delivering cost and efficiency gains across R&D, production, and clinical stages; in addition, the DTP (Direct-to-Patient) model is reshaping distribution channels. As a result, the industry’s overall profitability and innovation conversion efficiency are significantly improving.